Latest / Glaucoma, Vision & Longevity: Supplements & Science / Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients?

Transcript

Four New Glaucoma Developments From the Last Two Weeks — Which One Could Matter Most for Patients? · Glaucoma, Vision & Longevity: Supplements & Science

• 0:00
  SPEAKER_00: Four new glaucoma developments from the last two weeks.
• 0:02
  SPEAKER_00: Which one could matter most for patients?
• 0:05
  SPEAKER_00: Between August 21 and September 4, 2026, four glaucoma developments attracted attention.
• 0:11
  SPEAKER_00: G01, RHNGF V2 neuroprotective eye drops, acid sphingomyelinase, and ceramide metabolism as retinal ganglion cell targets.
• 0:21
  SPEAKER_00: Optical coherence tomography and geography for earlier progression detection.
• 0:25
  SPEAKER_00: NCX470, now called K911, approaching United States regulatory review, they are not equally important.
• 0:33
  SPEAKER_00: One is already available as a diagnostic technology, one is close to possible approval, but appears to be an incremental pressure-lowering improvement.
• 0:43
  SPEAKER_00: The other two could eventually change the biology of glaucoma, but both remain uncertain and relatively early.
• 0:50
  SPEAKER_00: This assessment uses information available through through September, 2026, with the current regulatory status checked through September 11th, 2026.
• 1:00
  SPEAKER_00: Important, the probabilities below are informed estimates, not clinical trial results or regulatory predictions.
• 1:07
  SPEAKER_00: Changing care means becoming sufficiently useful that it changes routine glaucoma management within approximately the next 5 to 10 years.
• 1:16
  SPEAKER_00: At a glance comparison for the full table, please open this article on VisualFieldTest.com.
• 1:22
  SPEAKER_00: The short answer.
• 1:23
  SPEAKER_00: Most likely to help patients in the next five to ten years.
• 1:27
  SPEAKER_00: NCX470K911 is the most likely to produce a measurable patient benefit because it has already completed large phase 3 trials and has entered regulatory review.
• 1:38
  SPEAKER_00: Most likely to improve glaucoma monitoring.
• 1:41
  SPEAKER_00: Optical coherence tomography angiography is the most immediately useful development.
• 1:46
  SPEAKER_00: It may identify progression roughly two years before visual field progression in some patients, although it is not perfect and does not directly treat glaucoma.
• 1:56
  SPEAKER_00: Highest upside G01 RHEF V2 has the greatest potential upside because it aims to protect retinal ganglion cells independently of intraocular pressure.
• 2:06
  SPEAKER_00: However, its current evidence is much weaker than the evidence supporting NCX470.
• 2:12
  SPEAKER_00: Most interesting biological discovery.
• 2:14
  SPEAKER_00: The acid sphingomyelinase ceramide pathway may reveal a new way to protect retinal ganglion cells, but it is still a target rather than a treatment.
• 2:23
  SPEAKER_00: G01 RHNGFV2 Neuroprotective Eye Drops.
• 2:28
  SPEAKER_00: What was reported?
• 2:29
  SPEAKER_00: G01 is an investigational eyedrop being developed in China for optic nerve injury associated with open angle glaucoma.
• 2:37
  SPEAKER_00: A phase two study was updated on August 24, 2026, after being first posted on August 20th, just outside the requested date range.
• 2:46
  SPEAKER_00: The randomized double mask study plans to enroll approximately 90 patients with progressing primary open angle glaucoma.
• 2:54
  SPEAKER_00: It compares G01 concentrations of 100 micrograms per milliliter and 200 micrograms per milliliter with placebo.
• 3:03
  SPEAKER_00: The study's primary outcome is change in visual field mean deviation after approximately 24 weeks of treatment with additional structural, electrophysiological, pharmacokinetic, and immunogenicity measurements.
• 3:16
  SPEAKER_00: Completion is estimated for late 2027.
• 3:19
  SPEAKER_00: A separate phase 1 study in healthy volunteers is testing single and repeated doses of 100, 200, and 400 micrograms per milliliter.
• 3:28
  SPEAKER_00: No public clinical efficacy results were available by September 4, 2026.
• 3:34
  SPEAKER_00: What is RHNGF V2 supposed to do?
• 3:37
  SPEAKER_00: Nerve growth factor is a neurotrophic protein involved in neuronal survival and repair.
• 3:43
  SPEAKER_00: The goal is not to lower eye pressure, but to make retinal ganglion cells more resistant to injury.
• 3:49
  SPEAKER_00: Public company information identifies GRO1's active ingredient as recombinant human nerve growth factor variant 2.
• 3:56
  SPEAKER_00: A related patent describes a modified nerve growth factor known as K34D, which appears to be the likely molecular identity of RHNGFV2, although the exact identity and characteristics of the clinical product have not been independently confirmed in a peer-reviewed clinical publication.
• 4:14
  SPEAKER_00: This is therefore a strong inference, not a fully established fact.
• 4:19
  SPEAKER_00: The proposed advantage of the modified molecule is greater signaling through the protective tropomyosin receptor kinase A pathway with less potentially harmful signaling through the P75 neurotrophin receptor.
• 4:32
  SPEAKER_00: The patent reports substantially reduced binding to the P75 receptor for K34D and even more receptor selectivity for a related double mutant molecule.
• 4:42
  SPEAKER_00: Strength of the evidence.
• 4:45
  SPEAKER_00: G01 is in a registered phase 2 glaucoma trial.
• 4:48
  SPEAKER_00: No GO1 efficacy results have been publicly reported.
• 4:52
  SPEAKER_00: A separate healthy volunteer safety and pharmacokinetic study is also registered.
• 4:57
  SPEAKER_00: A patent reports protective effects for K34D in rat ocular hypertension models.
• 5:02
  SPEAKER_00: Earlier human research with conventional recombinant human nerve growth factor established short-term safety, but did not demonstrate statistically significant neuroenhancement.
• 5:12
  SPEAKER_00: Animal evidence.
• 5:14
  SPEAKER_00: In a patent described RAT model of chronic ocular hypertension, treatment began after pressure elevation had already occurred.
• 5:22
  SPEAKER_00: K34D eye drops did not lower intraocular pressure, but they were associated with less retinal ganglion cell loss, less optic nerve axon damage, better pattern electroretinogram responses.
• 5:35
  SPEAKER_00: In one experiment, retinal ganglion cell loss was approximately 59% in vehicle-treated animals versus 31% with K34D, a roughly 50% relative reduction in cell loss.
• 5:47
  SPEAKER_00: However, the groups were small.
• 5:49
  SPEAKER_00: The work was reported in a patent rather than an independent peer-reviewed paper.
• 5:53
  SPEAKER_00: And the findings have not yet been replicated publicly by unrelated laboratories.
• 6:00
  SPEAKER_00: Human evidence for the nerve growth factor class A phase 1B randomized trial gave conventional recombinant human nerve growth factor to 40 patients and vehicle to 20 patients for eight weeks.
• 6:11
  SPEAKER_00: It found no treatment-related serious adverse events, no meaningful intraocular pressure effect, no statistically significant short-term improvement in visual fields or optical coherence tomography, ocular pain in approximately half of the nerve growth factor group, irritation, photophobia, and other surface symptoms in some patients.
• 6:33
  SPEAKER_00: The researchers noted that the trial was too short and too small to test true neuroprotection.
• 6:38
  SPEAKER_00: Still, the absence of a clear short-term functional signal is important.
• 6:43
  SPEAKER_00: It means that the modified G01 molecule must prove that it is meaningfully better than conventional nerve growth factor, not merely safer or more selective.
• 6:53
  SPEAKER_00: Biological plausibility.
• 6:55
  SPEAKER_00: The biological rationale is strong enough to justify clinical testing.
• 6:59
  SPEAKER_00: Retinal ganglion cells depend on neurotrophic support.
• 7:03
  SPEAKER_00: Glaucoma involves axonal injury, impaired transport, metabolic stress, and eventual cell death.
• 7:09
  SPEAKER_00: Neurotrophic signaling could theoretically preserve stressed but living retinal ganglion cells.
• 7:14
  SPEAKER_00: The patent data suggest a possible advantage from modifying receptor selectivity.
• 7:19
  SPEAKER_00: The main biological problem is delivery.
• 7:22
  SPEAKER_00: A topical eye drop must reach the retina and optic nerve in an adequate concentration.
• 7:27
  SPEAKER_00: The cornea, anterior chamber, lens, vitreous, and retinal barriers make posterior segment delivery difficult.
• 7:35
  SPEAKER_00: A large dose may be needed, which could worsen surface pain or irritation.
• 7:39
  SPEAKER_00: Potential magnitude of benefit.
• 7:41
  SPEAKER_00: Maximum plausible benefit.
• 7:43
  SPEAKER_00: If the animal findings translate unusually well to humans, G01 could slow retinal ganglion cell death by a substantial amount, delay visual field progression, provide benefit even when intraocular pressure is already at target, possibly improve function in retinal ganglion cells that are impaired but not yet dead.
• 8:04
  SPEAKER_00: Most realistic benefit.
• 8:06
  SPEAKER_00: The more realistic initial outcome would be a modest slowing of progression, perhaps in a subgroup of patients with active disease, despite acceptable intraocular pressure.
• 8:15
  SPEAKER_00: A benefit of approximately 10 to 25% slower functional deterioration would be clinically useful, but would not constitute a cure.
• 8:24
  SPEAKER_00: The possibility of a 30 to 50% reduction in progression is biologically conceivable but currently speculative.
• 8:31
  SPEAKER_00: Risks.
• 8:32
  SPEAKER_00: The major known concern is tolerability.
• 8:34
  SPEAKER_00: Conventional nerve growth factor produce substantial ocular pain and irritation in the phase 1B trial.
• 8:41
  SPEAKER_00: A modified molecule may have a better profile, but this has not yet been demonstrated in patients.
• 8:46
  SPEAKER_00: Other concerns include ocular surface inflammation, photophobia and discomfort, immunogenicity against a repeated protein treatment, insufficient retinal exposure, possible unintended effects on sensory nerves or inflammatory signaling, the need for multiple daily doses, likely patient population.
• 9:06
  SPEAKER_00: The most likely initial target would be patients with progressing open-angle glaucoma, intraocular pressure already reasonably controlled, mild to moderate disease with surviving retinal ganglion cells, documented structural or visual field progression.
• 9:21
  SPEAKER_00: Patients with advanced glaucoma could benefit from preservation of remaining vision, but a treatment cannot rescue retinal ganglion cells that have already died.
• 9:30
  SPEAKER_00: Does it work independently of intocular pressure?
• 9:33
  SPEAKER_00: Probably yes.
• 9:35
  SPEAKER_00: The patent experiments reported no intraocular pressure lowering, yet showed retinal ganglion cell and axon protection.
• 9:42
  SPEAKER_00: The current phase two trial also appears designed for patients with relatively controlled pressure, strengthening the idea that GR1 is intended as an adjunctive, pressure-independent treatment.
• 9:54
  SPEAKER_00: Could it preserve or restore vision?
• 9:57
  SPEAKER_00: Preserve vision?
• 9:58
  SPEAKER_00: Potentially, yes.
• 9:59
  SPEAKER_00: Restore lost function?
• 10:00
  SPEAKER_00: Possibly, but only if some retinal ganglion cells are dysfunctional rather than permanently lost.
• 10:06
  SPEAKER_00: Regenerate dead retinal ganglion cells and long optic nerve axons, not demonstrated.
• 10:11
  SPEAKER_00: Classification.
• 10:12
  SPEAKER_00: Potential treatment breakthrough.
• 10:14
  SPEAKER_00: Estimated probabilities?
• 10:16
  SPEAKER_00: Probability of ultimately changing glaucoma care, 15-30%.
• 10:21
  SPEAKER_00: Probability of producing clinically meaningful benefit, 15-25%.
• 10:26
  SPEAKER_00: Probability of meaningful benefit in advanced glaucoma, 10-20%.
• 10:30
  SPEAKER_00: Earliest plausible availability around 2030 to 2033 in China, assuming successful phase 2 and later trials, later in the United States and Europe.
• 10:40
  SPEAKER_00: Acid sphingomyelinase and ceramide metabolism.
• 10:44
  SPEAKER_00: What was reported?
• 10:45
  SPEAKER_00: A study published on August 31, 2026, examined retinal tissue from human donors with and without glaucoma.
• 10:52
  SPEAKER_00: It found reduced sphingomyelin labeling in retinal ganglion cells, increased acid sphingomyelinase expression inside retinal ganglion cells, increased lysosomal acid sphingomyelinase activity, more retinal ganglion cells containing ceramide aggregates, no significant change in some related enzymes, including neutral sphingomyelinase and sphingomyelin syntases.
• 11:15
  SPEAKER_00: No significant overall increase in total retinal ganglion cell ceramide.
• 11:20
  SPEAKER_00: The findings suggest that glaucoma may involve a specific disruption of sphingomyelin and ceramide organization, rather than simply a generalized rise in total ceramide.
• 11:30
  SPEAKER_00: Why might this matter?
• 11:31
  SPEAKER_00: Acid sphingomyelinase breaks down sphingomyelin into ceramide.
• 11:36
  SPEAKER_00: Ceramide is not merely a structural lipid.
• 11:38
  SPEAKER_00: Depending on its location, concentration, and molecular form, it can influence.
• 11:43
  SPEAKER_00: Cell membrane organization, mitochondrial function, inflammation, apoptosis, communication between retinal ganglion cells and glial cells.
• 11:52
  SPEAKER_00: This gives the pathway a plausible connection to retinal ganglion cell degeneration.
• 11:57
  SPEAKER_00: Strength of the evidence.
• 11:59
  SPEAKER_00: Human evidence.
• 12:01
  SPEAKER_00: The 2026 human study is important because it directly examined glaucomatous retinal tissue rather than relying solely on animal models.
• 12:09
  SPEAKER_00: However, it was an observational tissue study.
• 12:12
  SPEAKER_00: It showed an association, not proof, that acid sphingomyelinase causes glaucoma progression.
• 12:18
  SPEAKER_00: The absence of a significant increase in total ceramide is particularly important.
• 12:22
  SPEAKER_00: It suggests that the harmful signal may depend on which ceramide species are present, which cells contain them, whether they form local aggregates, whether they are inside lysosomes, membranes, axons, or glial cells.
• 12:37
  SPEAKER_00: Animal and cell evidence.
• 12:38
  SPEAKER_00: Earlier work found that ocular hypertension increased acid sphingomyelinase activity in the retina and optic nerve head.
• 12:45
  SPEAKER_00: In one study, retinal activity increased by approximately 121%, while optic nerve head activity increased substantially as well.
• 12:54
  SPEAKER_00: Neutral sphingomyelinase activity did not show the same response.
• 12:58
  SPEAKER_00: Other experiments reported that reducing acid sphingomyelinase expression protected retinal ganglion cells and preserved function in mouse ocular hypertension models.
• 13:08
  SPEAKER_00: Ceramide toxicity has also been demonstrated in human-induced pluripotent stem cell-derived retinal ganglion cells and human optic nerve head astrocytes.
• 13:18
  SPEAKER_00: A 2024 study went further by examining individual ceramide species.
• 13:23
  SPEAKER_00: Mice lacking ceramide synthase 5 had lower levels of certain ceramides and were more resistant to ocular hypertensive retinal ganglion cell injury.
• 13:33
  SPEAKER_00: Pattern electroretinogram responses and retinal ganglion cell counts were better preserved than in normal mice.
• 13:40
  SPEAKER_00: Biological plausibility.
• 13:42
  SPEAKER_00: This is one of the better supported emerging biological pathways in glaucoma research because it has human tissue association, mechanistic cell data, multiple animal models, evidence involving both retinal ganglion cells and glial cells, a plausible relationship to inflammation and apoptosis.
• 14:00
  SPEAKER_00: However, the pathway is complicated.
• 14:02
  SPEAKER_00: Ceramide is not uniformly harmful.
• 14:05
  SPEAKER_00: It is involved in normal retinal maintenance, cell signaling, and membrane function.
• 14:11
  SPEAKER_00: Complete loss of acid sphingomyelinase has been associated with age-related retinal degeneration in animals, which suggests that indiscriminate long-term suppression could be harmful.
• 14:21
  SPEAKER_00: The most promising strategy may therefore be partial, cell-specific, or species-specific modulation rather than complete systemic acid sphingomyelinase blockade.
• 14:32
  SPEAKER_00: Potential magnitude of benefit, maximum plausible benefit, a successful treatment could reduce retinal ganglion cell apoptosis, suppress harmful glial-inflammatory signaling, work independently of intraocular pressure, protect retinal ganglion cell axons as well as cell bodies, complement conventional pressure-lowering treatment.
• 14:52
  SPEAKER_00: Most realistic benefit.
• 14:54
  SPEAKER_00: The realistic near-term possibility is a modest neuroprotective adjunct that slows progression, especially in patients whose disease continues despite adequate pressure reduction.
• 15:05
  SPEAKER_00: It is unlikely that an acid sphingomyelinase-directed therapy would restore established visual field loss.
• 15:11
  SPEAKER_00: Its likely role would be preservation, not regeneration.
• 15:15
  SPEAKER_00: Risks.
• 15:16
  SPEAKER_00: Potential risks include interference with normal lysosomal function, retinal toxicity from excessive suppression, systemic effects if the drug reaches the circulation, effects on immune cells and inflammatory pathways, difficulty selectively targeting retinal ganglion cells, poor penetration of topical drugs to the retina and optic nerve.
• 15:37
  SPEAKER_00: At present, there is also no validated selective glaucoma-specific acid sphingomyelinase inhibitor ready for clinical testing.
• 15:45
  SPEAKER_00: Likely patient population.
• 15:47
  SPEAKER_00: If a treatment is developed, it would most likely be used in early or moderate glaucoma with evidence of progression, normal tension glaucoma or pressure-controlled glaucoma.
• 15:58
  SPEAKER_00: Patients needing an adjunct to pressure lowering.
• 16:01
  SPEAKER_00: Possibly advanced glaucoma patients who still have meaningful remaining vision.
• 16:06
  SPEAKER_00: Does it work independently of intraocular pressure?
• 16:09
  SPEAKER_00: Probably yes.
• 16:10
  SPEAKER_00: The pathway appears to respond to ocular hypertensive and ischemic stress, but acts downstream of pressure-related injury.
• 16:17
  SPEAKER_00: It could therefore be relevant even when intraocular pressure is not high at the time of examination.
• 16:23
  SPEAKER_00: Could it preserve or restore vision?
• 16:25
  SPEAKER_00: Preserve vision?
• 16:26
  SPEAKER_00: Potentially yes.
• 16:28
  SPEAKER_00: Restore lost function.
• 16:29
  SPEAKER_00: Very unlikely based on current evidence.
• 16:32
  SPEAKER_00: Regenerate dead retinal ganglion cells.
• 16:34
  SPEAKER_00: No evidence.
• 16:35
  SPEAKER_00: Classification.
• 16:37
  SPEAKER_00: Promising biological target.
• 16:39
  SPEAKER_00: Estimated probabilities.
• 16:41
  SPEAKER_00: Probability of ultimately changing glaucoma care?
• 16:44
  SPEAKER_00: 10 to 25%.
• 16:45
  SPEAKER_00: Probability of producing clinically meaningful patient benefit, 10-20%.
• 16:50
  SPEAKER_00: Probability of meaningful benefit in advanced glaucoma, 10-20%.
• 16:54
  SPEAKER_00: Earliest plausible availability, approximately 2033 to 2038 or later.
• 16:59
  SPEAKER_00: Optical coherence tomography, angiography for earlier progression detection.
• 17:05
  SPEAKER_00: What was reported?
• 17:06
  SPEAKER_00: A study published online on September 3rd, 2026 compared optical coherence tomography, angiography, vessel density measurements, standard optical coherence tomography, retinal, nerve fiber layer measurements, visual field testing.
• 17:21
  SPEAKER_00: The study included 180 eyes from 116 patients, including patients with both early and established glaucoma.
• 17:28
  SPEAKER_00: During an average follow-up of approximately 5.1 years, progression was detected by at least one method in 107 eyes.
• 17:36
  SPEAKER_00: Optical coherence tomography angiography detected the earliest progression in 37.4 cent of progressing eyes.
• 17:42
  SPEAKER_00: Standard optical coherence tomography detected it first in 29.9.
• 17:46
  SPEAKER_00: Visual field testing detected it first in 24.3 cent.
• 17:50
  SPEAKER_00: Optical coherence tomography angiography changes preceded visual field progression by an average of 2.3 years.
• 17:56
  SPEAKER_00: Standard optical coherence tomography changes preceded visual field progression by approximately 1.5.
• 18:02
  SPEAKER_00: Years the trade-off was slightly lower specificity for optical coherence tomography angiography than for standard optical coherence tomography.
• 18:11
  SPEAKER_00: Why could this matter to patients?
• 18:14
  SPEAKER_00: Glaucoma treatment is most effective when progression is recognized early.
• 18:18
  SPEAKER_00: A patient may lose retinal ganglion cells for years before a standard visual field test clearly shows change.
• 18:24
  SPEAKER_00: Earlier detection could allow clinicians to confirm poor adherence sooner.
• 18:30
  SPEAKER_00: Intensify pressure-lowering treatment, add laser or surgical treatment earlier, identify patients who need closer follow-up.
• 18:38
  SPEAKER_00: Avoid falsely labeling stable disease as progressive by using several independent measurements.
• 18:43
  SPEAKER_00: The test does not itself protect the optic nerve.
• 18:46
  SPEAKER_00: Its value comes from enabling better decisions sooner.
• 18:49
  SPEAKER_00: Strength of the evidence.
• 18:51
  SPEAKER_00: This is the strongest of the four developments in terms of direct human evidence relevant to its proposed use.
• 18:57
  SPEAKER_00: It is a longitudinal human study with repeated testing and clinically meaningful follow-up.
• 19:03
  SPEAKER_00: However, several limitations matter.
• 19:06
  SPEAKER_00: It was retrospective rather than a prospective treatment impact trial.
• 19:10
  SPEAKER_00: It came from a specialized research cohort.
• 19:12
  SPEAKER_00: The study included only patients who had repeated high-quality optical coherence tomography, optical coherence tomography angiography, and visual field testing.
• 19:22
  SPEAKER_00: The study showed earlier detection, not improved vision or reduced blindness.
• 19:27
  SPEAKER_00: The cost effectiveness of routinely adding optical coherence tomography angiography remains uncertain.
• 19:33
  SPEAKER_00: Earlier detection only improves outcomes if clinicians act on it, and the earlier action changes the disease trajectory.
• 19:40
  SPEAKER_00: Early, moderate, and advanced glaucoma.
• 19:44
  SPEAKER_00: Early glaucoma.
• 19:45
  SPEAKER_00: This may be the most valuable group for optical coherence tomography angiography because visual field damage can be subtle and standard tests may be noisy.
• 19:55
  SPEAKER_00: Still, standard optical coherence tomography may already perform very well in early disease.
• 20:01
  SPEAKER_00: Optical coherence tomography angiography should therefore be viewed as a complement, not an automatic replacement.
• 20:07
  SPEAKER_00: Moderate glaucoma.
• 20:09
  SPEAKER_00: This is likely the most practical group.
• 20:11
  SPEAKER_00: Patients have enough remaining tissue for structural progression to be measurable, but visual field deterioration may already carry important functional consequences.
• 20:20
  SPEAKER_00: Advanced glaucoma, optical coherence tomography and geography, could be useful because standard retinal nerve fiber layer thickness can reach a measurement floor.
• 20:30
  SPEAKER_00: Once the retinal nerve fiber layer is very thin, additional loss may no longer be obvious on thickness measurements.
• 20:39
  SPEAKER_00: Vessel density changes may continue to provide information beyond that floor.
• 20:44
  SPEAKER_00: The limitation is image quality.
• 20:46
  SPEAKER_00: Severe glaucoma is often accompanied by poor fixation, low signal, segmentation errors, and artifacts.
• 20:52
  SPEAKER_00: One recent study reported that only approximately 53% of macular scans and 39% of peripapillary scans and severe glaucoma were free of artifacts.
• 21:02
  SPEAKER_00: Risks optical coherence tomography and geography is non-invasive, but its clinical risks are indirect.
• 21:08
  SPEAKER_00: False positive progression, unnecessary treatment escalation, additional cost, increased testing burden, misinterpretation of artifacts, overconfidence in a single vascular measurement.
• 21:20
  SPEAKER_00: A large artifact study found poor quality images in approximately one-third of analyzed optical coherence tomography angiography images.
• 21:28
  SPEAKER_00: Automated quality scores were not always reliable enough to identify all problematic scans.
• 21:33
  SPEAKER_00: Careful human review remains essential.
• 21:36
  SPEAKER_00: Does it work independently of intraocular pressure?
• 21:39
  SPEAKER_00: Optical coherence tomography angiography is not a treatment, so the question is different.
• 21:45
  SPEAKER_00: It can detect progression whether or not pressure appears high at a particular visit.
• 21:50
  SPEAKER_00: However, it does not replace pressure management.
• 21:53
  SPEAKER_00: Its purpose is to show whether the optic nerve is continuing to deteriorate, potentially prompting a lower pressure.
• 22:00
  SPEAKER_00: Target or additional treatment.
• 22:02
  SPEAKER_00: Could it preserve or restore vision?
• 22:05
  SPEAKER_00: Preserve vision indirectly if earlier detection leads to earlier effective treatment.
• 22:10
  SPEAKER_00: Restore lost function?
• 22:12
  SPEAKER_00: No.
• 22:12
  SPEAKER_00: Regenerate retinal ganglion cells?
• 22:14
  SPEAKER_00: No.
• 22:15
  SPEAKER_00: Classification.
• 22:16
  SPEAKER_00: Diagnostic breakthrough.
• 22:18
  SPEAKER_00: That classification should be understood carefully.
• 22:20
  SPEAKER_00: It is a potential breakthrough in monitoring and detection, not a breakthrough treatment.
• 22:25
  SPEAKER_00: Estimated probabilities.
• 22:27
  SPEAKER_00: Probability of changing glaucoma monitoring.
• 22:36
  SPEAKER_00: Probability of being useful in advanced glaucoma 40 to 60%.
• 22:40
  SPEAKER_00: Earliest plausible availability, already available, with broader integration over the next 1-5 years.
• 22:46
  SPEAKER_00: NCX 470 K911, approaching regulatory approval.
• 22:51
  SPEAKER_00: What was reported?
• 22:52
  SPEAKER_00: On August 27, 2026, the United States Food and Drug Administration accepted the new drug application for NCX 470, now called K911 by COA.
• 23:04
  SPEAKER_00: The product's proposed generic name is Bimataprost Grenade.
• 23:08
  SPEAKER_00: The application received a Prescription Drug User Fee Act target action date of April 30, 2027.
• 23:15
  SPEAKER_00: COA has projected a possible United States launch in the second half of 2027 if the product is approved.
• 23:21
  SPEAKER_00: It is important to distinguish acceptance for review from approval.
• 23:25
  SPEAKER_00: K911 is not yet approved.
• 23:28
  SPEAKER_00: How does it work?
• 23:29
  SPEAKER_00: K911 combines a bimataprost-like prostaglandin effect that increases uvioscleral outflow, a nitric oxide donating component intended to increase conventional trabecular outflow.
• 23:41
  SPEAKER_00: The result is a once-daily drop acting through two aqueous humor outflow pathways.
• 23:46
  SPEAKER_00: Strength of the evidence.
• 23:48
  SPEAKER_00: This is the most clinically advanced of the four developments.
• 23:50
  SPEAKER_00: The application is supported by two large phase 3 trials.
• 23:54
  SPEAKER_00: Mont Blanc, 691 randomized patients, with 661 analyzed.
• 24:00
  SPEAKER_00: Dinali, 696 patients.
• 24:03
  SPEAKER_00: In Mont Blanc, the 0.1% dose reduced intraocular pressure by approximately 8.0 to 9.7 mm of mercury.
• 24:11
  SPEAKER_00: It produced greater reductions than latinoprost at all six measured time points, with statistical superiority at 4 of 6 time points.
• 24:18
  SPEAKER_00: The most common adverse event was ocular or conjunctival hyperemia.
• 24:23
  SPEAKER_00: Dinali met its primary goal of demonstrating non-inferiority to latanoprost.
• 24:28
  SPEAKER_00: It produced statistically greater reductions at three of six time points, but overall superiority was not established.
• 24:36
  SPEAKER_00: The trial also included a 12-month safety extension, and the sponsor reported sustained intraocular pressure reduction without new safety signals.
• 24:44
  SPEAKER_00: What is the likely patient benefit?
• 24:47
  SPEAKER_00: The likely benefit is better pressure control, not direct neuroprotection.
• 24:51
  SPEAKER_00: The advantage over latanoprost appears to be real but modest.
• 24:55
  SPEAKER_00: In practice, the most useful patients may be those who need an additional 1 to 2 mm of mercury reduction, have a low target pressure, are close to needing combination treatment, have difficulty reaching target pressure with a single prostaglandin, may benefit from once-daily dosing, and an alternative mechanism.
• 25:16
  SPEAKER_00: The phase 3 studies largely enrolled patients with open-angle glaucoma or ocular hypertension, and in the Mont Blanc trial, required relatively high untreated intraocular pressure.
• 25:26
  SPEAKER_00: That means the results may not fully predict performance in normal tension glaucoma or in patients whose pressure is already low.
• 25:34
  SPEAKER_00: Risks.
• 25:35
  SPEAKER_00: The principal expected risks are those of a nitric oxide donating prostaglandin combination, conjunctival hyperemia, eye irritation, possible discontinuation because of tolerability, prostaglandin class effects such as eyelash changes, iris or periocular pigmentation, and deepening of the upper eyelid sulcus with longer-term use.
• 25:56
  SPEAKER_00: The available trials are reassuring regarding serious adverse events, but real-world tolerability and adherence will determine whether K911 is preferred over cheaper generic alternatives.
• 26:07
  SPEAKER_00: Early, moderate, and advanced glaucoma.
• 26:11
  SPEAKER_00: Early glaucoma K911 could be useful when pressure lowering is indicated, but a clinician wants a stronger single-agent effect.
• 26:19
  SPEAKER_00: It will not be necessary for every patient.
• 26:22
  SPEAKER_00: Moderate glaucoma.
• 26:24
  SPEAKER_00: This may be the most useful group, especially for patients requiring a lower target pressure but not yet ready for surgery.
• 26:31
  SPEAKER_00: Advanced glaucoma.
• 26:32
  SPEAKER_00: Advanced glaucoma patients often need very low pressure targets.
• 26:36
  SPEAKER_00: An additional pressure reduction could be valuable, but many will still require multiple medications, laser treatment, or surgery.
• 26:43
  SPEAKER_00: Does it work independently of intraocular pressure?
• 26:47
  SPEAKER_00: No.
• 26:47
  SPEAKER_00: Its entire clinical purpose is intraocular pressure reduction.
• 26:51
  SPEAKER_00: It may reduce the risk of future visual field loss by lowering pressure, but it does not directly repair injured retinal ganglion cells.
• 26:59
  SPEAKER_00: Could it preserve or restore vision?
• 27:01
  SPEAKER_00: Preserve vision?
• 27:02
  SPEAKER_00: Yes, indirectly through pressure reduction.
• 27:05
  SPEAKER_00: Restore lost function?
• 27:07
  SPEAKER_00: No evidence.
• 27:08
  SPEAKER_00: Regenerate retinal ganglion cells?
• 27:10
  SPEAKER_00: No.
• 27:10
  SPEAKER_00: Classification.
• 27:12
  SPEAKER_00: Incremental treatment improvement.
• 27:14
  SPEAKER_00: This does not mean unimportant.
• 27:15
  SPEAKER_00: A modestly stronger, once-daily pressure-lowering drug can be useful to many patients.
• 27:20
  SPEAKER_00: It simply means that K911 is more likely to improve existing glaucoma management than to redefine glaucoma treatment.
• 27:28
  SPEAKER_00: Estimated probabilities.
• 27:29
  SPEAKER_00: Probability of regulatory approval, approximately 70 to 85%.
• 27:34
  SPEAKER_00: Probability of changing routine glaucoma care, 60 to 80%.
• 27:38
  SPEAKER_00: Probability of producing meaningful patient benefit, 55 to 75%.
• 27:44
  SPEAKER_00: Earliest plausible United States availability, second half of 2027, if approved on or near the current regulatory timetable.
• 27:53
  SPEAKER_00: Direct comparison, which development has the highest upside?
• 27:56
  SPEAKER_00: G01, RHNGF V2.
• 27:59
  SPEAKER_00: It is the only one of the four that could, if successful, directly protect retinal ganglion cells independently of intraocular pressure.
• 28:07
  SPEAKER_00: Its ceiling is therefore much higher than that of another pressure-lowering eye drop or a diagnostic test.
• 28:13
  SPEAKER_00: The problem is that its current human evidence is insufficient, which has the highest probability of success.
• 28:19
  SPEAKER_00: NCX470K9111.
• 28:22
  SPEAKER_00: It has completed two large phase 3 trials, demonstrated non-inferior or sometimes superior pressure lowering compared with Latanoprost, and entered formal regulatory review.
• 28:33
  SPEAKER_00: Its probability of success is not 100% because regulatory review, manufacturing, labeling, safety, pricing, and market adoption can still introduce uncertainty.
• 28:43
  SPEAKER_00: Which has the shortest path to patients?
• 28:46
  SPEAKER_00: There are two answers.
• 28:48
  SPEAKER_00: Shortest overall path, optical coherence tomography and geography, because it is already clinically available.
• 28:55
  SPEAKER_00: Shortest path among new treatments, NCX470 K911, because a regulatory decision is scheduled for April 30th, 2027, which has the greatest potential relevance for advanced glaucoma.
• 29:07
  SPEAKER_00: G01 has the greatest potential because pressure-independent neuroprotection could help patients who continue to lose vision despite low intraocular pressure.
• 29:17
  SPEAKER_00: However, K911 has the greatest near-term practical relevance for advanced glaucoma because additional pressure lowering is an established way to reduce future risk.
• 29:28
  SPEAKER_00: Optical coherence tomography angiography may help detect progression beyond the standard optical coherence tomography measurement floor, but it cannot by itself prevent further damage, which has the greatest chance of restoring rather than merely preserving function.
• 29:44
  SPEAKER_00: G01 slash RHNGF V2, although the absolute probability remains low.
• 29:50
  SPEAKER_00: A nerve growth factor therapy might improve function in retinal ganglion cells that are stressed but still alive.
• 29:56
  SPEAKER_00: This is different from regenerating dead cells or rebuilding damaged optic nerve connections.
• 30:01
  SPEAKER_00: My estimate is chance of modest functional restoration in a subgroup if G01 works, 5 to 15%.
• 30:09
  SPEAKER_00: Chance of meaningful widespread restoration of lost visual fields within 5 to 10 years, well below 10%.
• 30:16
  SPEAKER_00: The other three developments are primarily about preserving existing function, not restoring lost vision.
• 30:22
  SPEAKER_00: Overall ranking.
• 30:24
  SPEAKER_00: Ranking by likely meaningful patient impact during the next 5 to 10 years.
• 30:29
  SPEAKER_00: NCX470 slash K911.
• 30:32
  SPEAKER_00: Most likely to reach patients and provide a modest, real-world benefit through better intraocular pressure control.
• 30:39
  SPEAKER_00: Optical coherence tomography angiography.
• 30:42
  SPEAKER_00: Already available and likely to become more useful for progression monitoring, especially when combined with standard optical coherence tomography and visual field testing.
• 30:51
  SPEAKER_00: G01, RHNGF V2.
• 30:55
  SPEAKER_00: The most exciting potential treatment, but the human evidence is currently too limited to rank it higher.
• 31:00
  SPEAKER_00: Acid sphingomyelinase and ceramide metabolism, a compelling biological pathway, but no clinical treatment or development program has yet demonstrated that manipulating it helps patients.
• 31:11
  SPEAKER_00: Ranking by transformative upside G01, RHNGF V2, Acid sphingomyelinase and ceramide metabolism, optical coherence tomography angiography, NCX470, K911, Ranking by Probability of Near-Term Success, NCX470, K911, Optical Coherence Tomography, Angiography, G01, RHNGF V2, Acid sphingomyelinase and ceramide metabolism.
• 31:35
  SPEAKER_00: Known facts, strong inferences, and speculation.
• 31:38
  SPEAKER_00: Known facts.
• 31:39
  SPEAKER_00: K911 has entered United States regulatory review with a target action date of April 30, 2027.
• 31:45
  SPEAKER_00: Two large phase III trials support its application.
• 31:48
  SPEAKER_00: Optical Coherence Tomography Angiography detected progression earlier than visual field testing in a 2026 human cohort.
• 31:56
  SPEAKER_00: G01 is in a phase 2 glaucoma trial, but no efficacy results are public.
• 32:02
  SPEAKER_00: Human glaucomatus retinal tissue shows altered sphingomyelin and acid sphingomyelase biology.
• 32:08
  SPEAKER_00: Animal and cell studies support a role for ceramide signaling in retinal ganglion cell injury.
• 32:13
  SPEAKER_00: Strong inferences K911 is likely to become available before either G01 or an acid sphingomyelinase directed therapy.
• 32:21
  SPEAKER_00: Optical coherence tomography angiography will probably become more important as an adjunctive monitoring tool, not as a replacement for visual fields or standard optical coherence tomography.
• 32:33
  SPEAKER_00: G01 is intended to act independently of intraocular pressure.
• 32:38
  SPEAKER_00: The most clinically useful ceramide therapy would probably need selective or partial pathway modulation rather than complete acid sphingomyelinase suppression.
• 32:47
  SPEAKER_00: Speculation GRO1 could meaningfully slow visual field progression in humans.
• 32:52
  SPEAKER_00: GRO1 could restore function in damaged but living retinal ganglion cells.
• 32:57
  SPEAKER_00: Ceramide modulation could become a successful human neuroprotective strategy.
• 33:02
  SPEAKER_00: Earlier optical coherence tomography and geography detection will necessarily translate into fewer cases of blindness.
• 33:10
  SPEAKER_00: K9011's modest pressure advantage will be large enough to change long-term visual outcomes compared with inexpensive generic prostaglandins.
• 33:19
  SPEAKER_00: Which one would I bet on?
• 33:21
  SPEAKER_00: If I were choosing the development most likely to make a meaningful difference to patients during the next 5 to 10 years, I would bet on NCX470K911.
• 33:31
  SPEAKER_00: It has the strongest development position, the clearest mechanism, large human trials, and a defined regulatory timetable.
• 33:40
  SPEAKER_00: Its benefit will probably be incremental, not revolutionary, but incremental pressure reduction can still matter, particularly for patients who need a lower target pressure.
• 33:50
  SPEAKER_00: Optical coherence tomography and geography.
• 33:54
  SPEAKER_00: For actual clinical practice, this may be the most immediately important development.
• 33:59
  SPEAKER_00: It is already available and could help clinicians recognize progression earlier.
• 34:04
  SPEAKER_00: Its effect on vision will depend on whether earlier detection leads to better treatment decisions.
• 34:09
  SPEAKER_00: G01, RHNGF V2.
• 34:13
  SPEAKER_00: This is the one I would watch most closely scientifically.
• 34:16
  SPEAKER_00: It has the best chance of becoming a true treatment breakthrough among the four, but the gap between encouraging animal results and reliable human neuroprotection is large.
• 34:26
  SPEAKER_00: Acid sphingomyelinase and ceramide metabolism.
• 34:29
  SPEAKER_00: This may eventually become important, but it is still a discovery stage opportunity.
• 34:34
  SPEAKER_00: It needs a selective drug, convincing animal replication, pharmacokinetic proof of retinal delivery, and human trials demonstrating preserved visual function.
• 34:43
  SPEAKER_00: Final judgment.
• 34:45
  SPEAKER_00: The safest prediction is K911.
• 34:47
  SPEAKER_00: The most exciting prediction is G01.
• 34:50
  SPEAKER_00: The most immediately useful prediction is optical coherence tomography and geography.
• 34:56
  SPEAKER_00: The most uncertain but biologically intriguing prediction is acid sphingomyelinase and ceramide metabolism.
• 35:03
  SPEAKER_00: If forced to choose only one development with the best combination of probability and patient impact, I would choose NCX470, K911.
• 35:12
  SPEAKER_00: If forced to choose the one that could most profoundly change the future of glaucoma treatment, I would choose G01 RHNGF V2, but with considerably less confidence.
• 35:23
  SPEAKER_00: All links to sources are available in the text version of this article.
• 35:27
  SPEAKER_00: You can find the full article at VisualFieldTest.com.
• 35:30
  SPEAKER_00: Thanks for listening.
• 35:32
  SPEAKER_00: To check your visual field, click the link at the bottom of this article or visit visualfieldtest.com.